Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies

• Published in: Handbook of experimental pharmacology Vol. 258; p. 443
• Main Authors: Leggio, Lorenzo, Falk, Daniel E, Ryan, Megan L, Fertig, Joanne, Litten, Raye Z
• Format: Journal Article
• Language: English
• Published: Germany 2020
• Subjects: Pharmacotherapy; Medication development; Alcohol use disorder; Clinical studies
• ISSN: 0171-2004
• DOI: 10.1007/164_2019_295

Compared to other medical disorders, including other brain diseases, the number of medications approved for alcohol use disorder (AUD) is very small. Disulfiram, naltrexone (oral and long-acting), and acamprosate are approved by the US Food and Drug Administration (FDA) to treat patients with AUD. These medications are also approved in other countries, including in Europe, where the European Medicines Agency (EMA) also approved nalmefene for AUD. Furthermore, baclofen was recently approved for AUD in France. These approved medications have small effect sizes, which are probably the consequence of the fact that they only work for some patients, yet a personalized approach to match the right medication with the right patient is still in its infancy. Therefore, research is needed to expand the armamentarium of medications that clinicians can use to treat their patients, as well as to better develop personalized approaches. This book chapter reviews other medications, beyond those approved by the FDA, that have shown efficacy in clinical trials, as well as medications which are still in the early stages of evaluation in human studies.